Roche reports new 6-year OCREVUS (ocrelizumab) data from MS study Roche announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed patients who were treated with OCREVUS® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in RMS and primary PPMS. September 13, 2019

Ardelyx receives FDA approval for IBSRELA® (Tenapanor) for treatment of IBS-C Ardelyx announced the FDA has approved IBSRELA® (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation in adults. IBSRELA is a minimally-absorbed small molecule that acts locally in the GI tract to inhibit the sodium-hydrogen exchanger NHE3.September 12, 2019